Groundbreaking new cancer treatment, capivasertib, approved by NHS, offering hope to thousands of women annually

In a significant advancement for breast cancer treatment, the NHS has approved the twice-daily pill capivasertib, particularly for those suffering from hormone receptor (HR)-positive, HER2-negative advanced breast cancer. This drug, which targets the AKT protein crucial for cancer cell multiplication, is expected to benefit around 3,000 women each year. Clinical trials have shown capivasertib can extend the period before cancer cells progress by an average of 4.2 months when combined with the hormone therapy fulvestrant, a remarkable improvement from previous therapies. Advocate Ellen Hughes, who credits capivasertib with enhancing her quality of life since beginning treatment, exemplifies the crucial role this medication can play in the lives of patients battling advanced breast cancer. The Institute of Cancer Research has heralded this milestone as a 'triumph' for British science, highlighting the extensive research and collaboration that made this breakthrough possible. Despite this hopeful announcement, healthcare professionals stress the immediate need for genetic testing to identify eligible patients, aiming to bring this innovative treatment to those who need it most without further delay. It is essential to note that while the drug provides hope, it is not a cure, and the approval by the NICE (National Institute for Health and Care Excellence) comes after prior rejection due to uncertainties in evidence, raising issues on the pace of drug approvals. Overall, this moment represents a blend of scientific achievement and patient advocacy combining to improve care and quality of life for individuals facing challenging cancer diagnoses, highlighting the pressing need for streamlined processes in bringing such vital medications to market.